deltatrials
Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06963216

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

A Phase III Open-Label Multi-Center Study of the Pharmacokinetics, Safety, and Efficacy of Coagadex in the Treatment of Adults With Acquired Factor X Deficiency Associated With Light Chain Amyloidosis

Sponsor: Kedrion S.p.A.

Conditions Acquired Factor X Deficiency
Interventions Coagadex(R)
Updated 3 times since 2025 Last updated: Feb 25, 2026 Started: Feb 28, 2026 Primary completion: Jun 30, 2027 Completion: Sep 30, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Acquired Factor X Deficiency and is currently actively recruiting participants. Kedrion S.p.A. leads this study, which shows 3 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshotNot Yet Recruiting~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshotNot Yet Recruiting~Feb 2026 – present · 5 months · monthly snapshotRecruiting

Change History

3 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  2. Sep 2025 — Feb 2026 [monthly]

    Not Yet Recruiting PHASE3

  3. Jun 2025 — Sep 2025 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Kedrion S.p.A.
  • Worldwide Clinical Trials
Data source: Kedrion S.p.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations